Nomethiazoles offer a three-pronged approach to the complex problem of neurodegenerative diseases.

Behavioral symptoms exacerbate the burden of Alzheimer’s disease, not only for the patient but for the caregiver as well. These symptoms frequently include both anxiety and agitation. According to the Alzheimer’s Association, a majority of patients with Alzheimer's disease experience agitation and anxiety. Such behaviors are associated with psychological distress and interfere with interpersonal relationships. They also impact the ability to perform or participate in daily living activities. There are many different therapies that can be prescribed for treatment of behavioral symptoms but they often produce additional unwanted effects and do not target the progression of the disease. There is an unmet medical need for a safe and effective therapy to treat the behavioral symptoms in patients with Alzheimer's disease.

Revivo’s unique approach potentially offers both clinically important behavioral and cognition-enhancing benefits in patients with earlier-stage disease and the potential to slow disease progression with long-term treatment. Nomethiazoles improve cognition and lower amyloid-beta and tau in multiple Alzheimer's models.



The Nomethiazole therapeutic class was discovered in the laboratory of Professor Greg Thatcher while at Queen's University, Kingston, Ontario. Professor Thatcher now holds the Hans W. Vahlteich Chair of Medicinal Chemistry in the Department of Medicinal Chemistry and Pharmacognosy at the University of Illinois College of Pharmacy, Chicago. 

A Phase-1 clinical trial of RIV-1061 in healthy volunteers demonstrated rapid and extensive absorption of RIV-1061. A series of new formulation prototypes have been developed. Based on preclinical assessments of these formulations, RIV-1061 is now staged to return to clinical evaluations under an Investigational New Drug Exemption (IND) in the USA. 

According to Dr. Elliott J. Mufson, Alla and Solomon Jesmer Chair in Aging at Chicago's Rush University Medical Center, "Preliminary evidence in several transgenic animal models of Alzheimer's Disease indicates that this compound has potential to improve synaptic efficiency providing evidence for therapeutic potential…".